vs

Side-by-side financial comparison of PROCEPT BioRobotics Corp (PRCT) and WisdomTree, Inc. (WT). Click either name above to swap in a different company.

WisdomTree, Inc. is the larger business by last-quarter revenue ($159.5M vs $83.1M, roughly 1.9× PROCEPT BioRobotics Corp). WisdomTree, Inc. runs the higher net margin — 25.5% vs -38.1%, a 63.5% gap on every dollar of revenue. On growth, WisdomTree, Inc. posted the faster year-over-year revenue change (47.5% vs 20.2%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs 22.1%).

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

WisdomTree, Inc. is a global exchange-traded fund (ETF) and exchange-traded product (ETP) sponsor and asset manager with headquarters in New York. WisdomTree launched its first ETFs in June 2006, and became one of the major ETF providers in the United States. WisdomTree sponsors different ETFs that span asset classes and countries worldwide. Categories include: U.S. and International Equity, Currency, Fixed Income and Alternatives.

PRCT vs WT — Head-to-Head

Bigger by revenue
WT
WT
1.9× larger
WT
$159.5M
$83.1M
PRCT
Growing faster (revenue YoY)
WT
WT
+27.3% gap
WT
47.5%
20.2%
PRCT
Higher net margin
WT
WT
63.5% more per $
WT
25.5%
-38.1%
PRCT
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
22.1%
WT

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
PRCT
PRCT
WT
WT
Revenue
$83.1M
$159.5M
Net Profit
$-31.6M
$40.6M
Gross Margin
64.9%
Operating Margin
-4.1%
37.2%
Net Margin
-38.1%
25.5%
Revenue YoY
20.2%
47.5%
Net Profit YoY
-27.9%
76.4%
EPS (diluted)
$-0.56
$0.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRCT
PRCT
WT
WT
Q1 26
$83.1M
$159.5M
Q4 25
$76.4M
$147.4M
Q3 25
$83.3M
$125.6M
Q2 25
$79.2M
$112.6M
Q1 25
$69.2M
$108.1M
Q4 24
$68.2M
$110.7M
Q3 24
$58.4M
$113.2M
Q2 24
$53.4M
$107.0M
Net Profit
PRCT
PRCT
WT
WT
Q1 26
$-31.6M
$40.6M
Q4 25
$-29.8M
$40.0M
Q3 25
$-21.4M
$19.7M
Q2 25
$-19.6M
$24.8M
Q1 25
$-24.7M
$24.6M
Q4 24
$-18.9M
$27.3M
Q3 24
$-21.0M
$-4.5M
Q2 24
$-25.6M
$21.8M
Gross Margin
PRCT
PRCT
WT
WT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
PRCT
PRCT
WT
WT
Q1 26
-4.1%
37.2%
Q4 25
-40.6%
40.5%
Q3 25
-27.8%
36.3%
Q2 25
-28.0%
30.8%
Q1 25
-39.7%
31.6%
Q4 24
-28.9%
31.7%
Q3 24
-38.4%
36.0%
Q2 24
-50.3%
31.3%
Net Margin
PRCT
PRCT
WT
WT
Q1 26
-38.1%
25.5%
Q4 25
-39.1%
27.1%
Q3 25
-25.7%
15.7%
Q2 25
-24.7%
22.0%
Q1 25
-35.8%
22.8%
Q4 24
-27.6%
24.7%
Q3 24
-35.9%
-4.0%
Q2 24
-48.0%
20.3%
EPS (diluted)
PRCT
PRCT
WT
WT
Q1 26
$-0.56
$0.28
Q4 25
$-0.54
$0.28
Q3 25
$-0.38
$0.13
Q2 25
$-0.35
$0.17
Q1 25
$-0.45
$0.17
Q4 24
$-0.34
$0.20
Q3 24
$-0.40
$-0.13
Q2 24
$-0.50
$0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRCT
PRCT
WT
WT
Cash + ST InvestmentsLiquidity on hand
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$347.7M
Total Assets
$487.1M
$1.8B
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRCT
PRCT
WT
WT
Q1 26
$245.6M
Q4 25
$286.5M
Q3 25
$294.3M
Q2 25
$302.7M
Q1 25
$316.2M
Q4 24
$333.7M
Q3 24
$196.8M
Q2 24
$214.1M
$132.5M
Total Debt
PRCT
PRCT
WT
WT
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
PRCT
PRCT
WT
WT
Q1 26
$347.7M
Q4 25
$365.9M
$413.7M
Q3 25
$380.3M
$373.4M
Q2 25
$385.8M
$445.1M
Q1 25
$389.2M
$415.6M
Q4 24
$402.2M
$400.0M
Q3 24
$241.2M
$374.9M
Q2 24
$251.8M
$445.6M
Total Assets
PRCT
PRCT
WT
WT
Q1 26
$487.1M
$1.8B
Q4 25
$508.1M
$1.5B
Q3 25
$511.5M
$1.4B
Q2 25
$513.1M
$1.1B
Q1 25
$519.4M
$1.0B
Q4 24
$534.0M
$1.0B
Q3 24
$374.1M
$1.0B
Q2 24
$374.4M
$964.1M
Debt / Equity
PRCT
PRCT
WT
WT
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRCT
PRCT
WT
WT
Operating Cash FlowLast quarter
$18.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.44×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRCT
PRCT
WT
WT
Q1 26
$18.0M
Q4 25
$-10.3M
$147.9M
Q3 25
$-6.6M
$48.1M
Q2 25
$-15.0M
$38.8M
Q1 25
$-17.0M
$6.4M
Q4 24
$-32.4M
$113.5M
Q3 24
$-18.8M
$47.7M
Q2 24
$-15.7M
$32.2M
Free Cash Flow
PRCT
PRCT
WT
WT
Q1 26
Q4 25
$-12.2M
$147.7M
Q3 25
$-9.5M
$48.0M
Q2 25
$-17.8M
$38.7M
Q1 25
$-18.8M
$6.3M
Q4 24
$-33.6M
$113.3M
Q3 24
$-19.0M
$47.7M
Q2 24
$-16.8M
$32.2M
FCF Margin
PRCT
PRCT
WT
WT
Q1 26
Q4 25
-15.9%
100.2%
Q3 25
-11.4%
38.2%
Q2 25
-22.5%
34.4%
Q1 25
-27.2%
5.9%
Q4 24
-49.2%
102.4%
Q3 24
-32.6%
42.1%
Q2 24
-31.4%
30.1%
Capex Intensity
PRCT
PRCT
WT
WT
Q1 26
Q4 25
2.4%
0.1%
Q3 25
3.4%
0.0%
Q2 25
3.5%
0.1%
Q1 25
2.7%
0.0%
Q4 24
1.7%
0.1%
Q3 24
0.4%
0.0%
Q2 24
2.0%
0.0%
Cash Conversion
PRCT
PRCT
WT
WT
Q1 26
0.44×
Q4 25
3.70×
Q3 25
2.44×
Q2 25
1.57×
Q1 25
0.26×
Q4 24
4.15×
Q3 24
Q2 24
1.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

WT
WT

Advisory fees$134.9M85%
Other$6.1M4%
Third-party distribution fees$5.8M4%
Management fees$5.2M3%
Sales and business development$4.2M3%
Professional fees$3.3M2%

Related Comparisons